Circulating amyloid beta 1-40 peptide as an associate of renal function decline

Background Recent evidence suggests that Alzheimer's amyloid-beta (1-40) (Αβ1-40), an emerging biomarker of cardiovascular disease, may be involved in the heart-brain-renal axis. We aimed to comprehensively explore the association between circulating Aβ1-40 levels and renal function and its cli...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Mavraganis, Georgios (VerfasserIn) , Georgiopoulos, Georgios (VerfasserIn) , Zervas, Georgios (VerfasserIn) , Aivalioti, Evmorfia (VerfasserIn) , Delialis, Dimitrios (VerfasserIn) , Petropoulos, Ioannis (VerfasserIn) , Rachiotis, Nikolaos (VerfasserIn) , Konstantaki, Christina (VerfasserIn) , Moustou, Chrysoula (VerfasserIn) , Dimopoulou, Maria-Aggeliki (VerfasserIn) , Sachse, Marco (VerfasserIn) , Tual-Chalot, Simon (VerfasserIn) , Sopova, Kateryna (VerfasserIn) , Psimmenou, Erasmia (VerfasserIn) , Stellos, Konstantinos (VerfasserIn) , Stamatelopoulos, Kimon (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: May 2025
In: European journal of clinical investigation
Year: 2025, Jahrgang: 55, Heft: 5, Pages: 1-13
ISSN:1365-2362
DOI:10.1111/eci.70006
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1111/eci.70006
Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/eci.70006
Volltext
Verfasserangaben:Georgios Mavraganis, Georgios Georgiopoulos, Georgios Zervas, Evmorfia Aivalioti, Dimitrios Delialis, Ioannis Petropoulos, Nikolaos Rachiotis, Christina Konstantaki, Chrysoula Moustou, Maria-Aggeliki Dimopoulou, Marco Sachse, Simon Tual-Chalot, Kateryna Sopova, Erasmia Psimmenou, Konstantinos Stellos, Kimon Stamatelopoulos
Beschreibung
Zusammenfassung:Background Recent evidence suggests that Alzheimer's amyloid-beta (1-40) (Αβ1-40), an emerging biomarker of cardiovascular disease, may be involved in the heart-brain-renal axis. We aimed to comprehensively explore the association between circulating Aβ1-40 levels and renal function and its clinical relevance. Methods Consecutively recruited subjects in the Athens Angiometabolic Registry with measured Aβ1-40 plasma levels (n = 811) were analysed. Αβ1-40 was measured by enzyme-linked immunosorbent assay and glomerular filtration rate (GFR) was calculated using the abbreviated four-variable Modification of Diet in Renal Disease (MDRD) formula. All-cause mortality was the main clinical endpoint across a median follow-up of 47 months. Results Cross-sectionally, a bidirectional association between Αβ1-40 [adjusted odds ratio (adjOR) = 3.67 for highest tertile of Αβ1-40 and chronic kidney disease (CKD) stage ≥3, p < .001] and CKD stage ≥3 (adjOR = 3.52 for association with highest Aβ1-40 tertile, p < .001) was observed. Longitudinally, increased Αβ1-40 at baseline was associated with decline in renal function at follow-up (adjOR for CKD stage ≥3 = 2.26, p = .033). Similarly, longitudinal changes in Aβ1-40 were inversely associated with changes in GFR (OR = .77 per 1 SD increase in Aβ1-40, p = .006). Aβ1-40 was associated with all-cause mortality, independently of traditional risk factors (hazard ratio = 1.20 per 1 SD increase in Aβ1-40, p = .016). An indirect effect of GFR on the association between Aβ1-40 and mortality (p < .05) with an estimated indirect-to-total effect ratio of .334, but not of Αβ1-40 on GFR with mortality, was observed. Conclusions In a population with a wide range of GFR, we found a bidirectional association between Αβ1-40 levels and renal function. The association of Αβ1-40 with all-cause mortality was partly mediated by lower GFR.
Beschreibung:Online veröffentlicht: 24. Februar 2025
Gesehen am 02.06.2025
Beschreibung:Online Resource
ISSN:1365-2362
DOI:10.1111/eci.70006